Status:
COMPLETED
Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Congenital Bleeding Disorder
Haemophilia A
Eligibility:
MALE
Brief Summary
This study is conducted in Europe. The purpose of this retrospective study is to collect additional safety information of patients with haemophilia and inhibitors who are treated with rFVIIa.
Detailed Description
Non-interventional, retrospective data collection on standard treatments of haemophilia A and B patients with inhibitors in the UK.
Eligibility Criteria
Inclusion
- All haemophilia A or B patients with inhibitors treated with NovoSeven are included
Exclusion
- No exclusion criteria beyond the contraindications described in the approved product information text
Key Trial Info
Start Date :
January 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00853086
Start Date
January 1 2008
End Date
June 1 2011
Last Update
November 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Crawley, United Kingdom, RH11 9RT